There are currently 25 vaccines to fight COVID-19 in clinical evaluation, another 139 vaccines in a pre-clinical stage, and many more being researched.
But many of those vaccines, if they are at all successful, might not produce an immune response in portions of the population. That’s because some people’s bodies will react differently to the materials in the vaccine that are supposed to stimulate virus-fighting T cells.
And so just figuring out how much coverage a vaccine has, meaning, how many people it will stimulate to mount an immune response, is a big part of the vaccine puzzle.
With that challenge in mind, scientists at Massachusetts Institute of Technology on Monday unveiled a machine learning approach that can predict the probability that a particular vaccine design will reach a certain proportion of the population. That doesn’t mean they can guarantee its effectiveness, but the scientists’ work can aid in knowing up-front whether a given vaccine will have large gaps in who it can help.
The good news is, the MIT scholars have used their approach to design a novel COVID-19 vaccine on the computer that has far better coverage than many of the designs that have been published in the literature this year. They’re now testing the design in animals.
The bad news is, there could very well be large gaps in coverage of some of the existing vaccines already being explored by companies and labs, according to one of the authors of the report, David K. Gifford, who is with MIT’s Computer Science and Artificial Intelligence Laboratory.
“While they may protect more than 50% of the population, certain individuals and older individuals may not be protected,” Gifford told ZDNet in an email, when asked about vaccines currently under trial and in development.
The long path to a vaccine
Vaccines in development were not the direct subject of the work. Most of those vaccines are closed designs; no one knows exactly how they are composed. Instead, Gifford and colleagues designed vaccines from scratch, and then analyzed how effective they are, and extrapolated the findings to a group of vaccines whose composition is known.
Based on that, one can infer there might be problems with vaccines whose exact composition is not known.
It must be borne in mind that any in silico vaccine design such as the kind discussed here is only the beginning of a process that can take years to go through in vivo testing, in animals and then in humans, to establish both safety (non-toxicity), and efficacy, meaning that it actually confers a significant immune response.
But the work shows the ability of large computer models to dramatically speed up the initial work of searching through many, many possible combinations within a universe of possible ingredients, a search that can itself take years at the front end of a drug development pipeline.
This is the latest in large-scale, in-silico efforts against pathogens seen this year from MIT. Back in March, ZDNet reported on how MIT scientists used large-scale machine learning to search many combinations of compounds to come up with a novel antibiotic for a germ nothing else could kill.
Image Credit: Amanda Scott/Envato
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News This Week
Frank Boehm contributes to ‘Modern Approaches to Augmentation of Brain Function’
Modern Approaches to Augmentation of Brain Function Available from Springer Press This book covers recent advances in neural technology that provide for enhancements for brain function. It addresses a broad range of neural phenomena [...]
COVID-19: Experimental vaccine lasts 1 month at room temperature
Although the currently available COVID-19 vaccines are highly effective, limited manufacturing capacity and the need for cold-chain storage hinder their global distribution. A recent study tested the efficacy of a new adeno-associated virus (AAV) [...]
COVID vaccines hold up against severe Delta: US data
Fully vaccinated people were 11 times less likely to die of COVID and 10 times less likely to be hospitalized compared to the unvaccinated since highly contagious Delta became the most common variant, US [...]
How much protection COVID-19 vaccines give you against the Delta variant – best available data
The highly-infectious Delta coronavirus variant has spread to at least 174 countries worldwide, from the US to Australia, causing a surge in COVID-19 cases. The variant has mutations that help it partially escape the immune response produced by [...]
Without these lipid shells, there would be no mRNA vaccines for COVID-19
Fragile mRNA molecules used in COVID-19 vaccines can’t get into cells on their own. They owe their success to lipid nanoparticles that took decades to refine. Messenger RNA (mRNA) is having a moment. This [...]
COVID-19 Has Revealed Critical Knowledge Gaps on the Transmission of Respiratory Viruses
The COVID-19 pandemic has revealed critical knowledge gaps and assumptions concerning how respiratory viruses spread between hosts. Traditionally thought to be spread mainly through large respiratory droplets produced by the coughs and sneezes of sick individuals, [...]
Beyond coronavirus: the virus discoveries transforming biology
SARS-CoV-2 is just one of nonillions of viruses on our planet, and scientists are rapidly identifying legions of new species. Mya Breitbart has hunted novel viruses in African termite mounds, Antarctic seals and water [...]
COVID Vaccines Compared
There are three COVID-19 vaccines approved for use in the U.S. The Pfizer, Moderna, and Johnson & Johnson vaccines are all highly effective in protecting you from the virus that causes COVID-19. The Pfizer [...]
Covid Long-Haulers are Fighting for their Future
Many people with long COVID feel that science is failing them. Neglecting them could make the pandemic even worse. While watching the scientific community grapple with long COVID, I have thought a lot about a [...]
Experts Identify New COVID Variation in South Africa – What’s Known So Far
As a team of South African researchers we have identified a new lineage of SARS-CoV-2, the virus causing COVID-19. A lineage represents a genetically distinct virus population with a common ancestor. This virus may be designated as a variant [...]
Biden administration prepares for ‘reasonable likelihood’ of another serious pandemic
Citing the possibility of another serious pandemic, the Biden administration on Friday laid out a plan to transform the nation’s ability to respond to major biological threats. As staggering as the COVID-19 pandemic has been, [...]
Video: How Doctors Can Predict Who Dies From COVID
How doctors can predict which patients are more likely to die of COVID Several studies have come out about the COVID prognosis. As a result, we now have a powerful way to predict [...]
New COVID-19 Mu Variant Named a “Variant of Interest”
Though Delta continues to be the dominant COVID-19 strain, the World Health Organization (WHO) now says there's a new variant to keep your eye on. The B.1.621 variant, also called Mu, has just been [...]
Coronavirus vaccines cut risk of long Covid, study finds
Being fully vaccinated against Covid-19 not only cuts the risk of catching it, but also of an infection turning into long Covid, research led by King's College London suggests. It shows that in the [...]
Moderna Creates Twice as Many Antibodies as Pfizer, Study Shows
Moderna Inc.’s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations. A study of almost [...]
Covid variant detected in South Africa ‘most mutated variant so far’
A coronavirus variant first detected in South Africa 'could be more infectious' than other mutations and have the potential to 'evade vaccines', scientists have said. The C.1.2 strain, which is linked to 'increased transmissibility', is more mutations away from [...]
